<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patients with cancer: Clinical features and diagnosis of cognitive impairment and delirium</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patients with cancer: Clinical features and diagnosis of cognitive impairment and delirium</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Patients with cancer: Clinical features and diagnosis of cognitive impairment and delirium</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacynthe Rivest, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon Levenson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan M Silver, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan D Block, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2497368731"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cognitive impairment frequently occurs in patients with cancer and may negatively affect functioning and quality of life [<a href="#rid1">1,2</a>]. A subset of cancer patients with cognitive impairment can experience delirium, which is a neuropsychiatric syndrome [<a href="#rid3">3,4</a>]. Delirium is distressing for patients and families, can interfere with recognition and management of symptoms such as pain, and is associated with increased morbidity and mortality.</p><p>This topic reviews the clinical features of cognitive impairment in patients diagnosed with and treated for cancer, as well as the clinical features and diagnosis of delirium. Other topics discuss cognitive function after cancer treatment (ie, in cancer survivors), the clinical features and diagnosis of delirium in palliative care, the management of delirium in cancer patients, and the clinical features and diagnosis of other psychiatric disorders in cancer patients.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16347.html" rel="external">"Cognitive function after cancer and cancer treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2196.html" rel="external">"Approach to symptom assessment in palliative care", section on 'Delirium'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4853.html" rel="external">"Management of psychiatric disorders in patients with cancer", section on 'Delirium'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4858.html" rel="external">"Patients with cancer: Overview of the clinical features and diagnosis of psychiatric disorders"</a>.)</p><p></p><p class="headingAnchor" id="H1512416937"><span class="h1">COGNITIVE IMPAIRMENT</span></p><p class="headingAnchor" id="H3058493593"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Based upon multiple studies, patients with cancer, including cancer located outside of the central nervous system, often report cognitive decline [<a href="#rid5">5,6</a>]. However, the magnitude of the changes is typically modest, and functional impairment is usually minimal [<a href="#rid5">5,7,8</a>].</p><p>Standardized testing of patients with cancer indicates that cognitive dysfunction can occur in several domains, including [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Attention</p><p class="bulletIndent1"><span class="glyph">●</span>Concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Executive functions (eg, planning, problem solving, and response inhibition)</p><p class="bulletIndent1"><span class="glyph">●</span>Information processing speed</p><p class="bulletIndent1"><span class="glyph">●</span>Memory </p><p></p><p>In addition, patient self-reports (rather than standardized tests) indicate that the prevalence of cognitive impairment is greater in patients with cancer than the general population and may adversely affect patient functioning and quality of life. Patient self-reports may provide information about subtle cognitive changes that are not detected by standard neuropsychological tests, but self-reports are generally nonspecific and influenced by beliefs and stress [<a href="#rid6">6</a>]. A nationally representative survey identified individuals with a history of cancer (n &gt;1300) and individuals with no history of cancer; after controlling for potential confounding factors (eg, age, education, and self-rated general health), the analyses found that self-rated memory problems were present in more individuals with a history of cancer than controls (14 versus 8 percent) [<a href="#rid9">9</a>].</p><p>The duration of cognitive impairment in patients with cancer varies, and may extend beyond the acute illness and its treatment.</p><p class="headingAnchor" id="H1266814438"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Although the prevalence of cognitive impairment in cancer patients varies due to differences in study populations and type of assessment [<a href="#rid5">5,8</a>], reviews estimate that impairment after diagnosis of cancer but prior to treatment occurs in approximately 20 to 30 percent of patients [<a href="#rid5">5,6</a>].</p><p>Cancer treatments are associated with neuropsychological deficits in up to 75 percent of patients [<a href="#rid5">5,6</a>]. However, in some cases, cancer-treatment related deficits are subtle and are associated with little or no functional impairment.</p><p>There are no established risk factors for cognitive impairment in patients with cancer, but increased age (eg, age ≥65 years) and decreased baseline cognitive reserve (intellectual capacity) appear to increase the risk [<a href="#rid1">1,5,6,10</a>]. In older patients, cancer-related cognitive decline may be more likely in those with fatigue, sleep problems, and frailty [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1442642942"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The neurobiologic mechanisms by which cognitive function declines in cancer patients have not been completely elucidated. Nonetheless, both structural and functional central nervous system changes have been correlated with cognitive impairment. It is likely that different mechanisms contribute and that cognitive dysfunction in some patients reflects an interaction between multiple factors [<a href="#rid2">2</a>].</p><p>Potential causes of cognitive impairment include [<a href="#rid1">1,2,5,6,10,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Brain metastases – New-onset cognitive impairment in cancer patients should prompt brain imaging to look for brain metastases, especially in patients with primary tumors that have a relatively high rate of metastasizing to the brain. (See  <a class="medical medical_review" href="/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases", section on 'Primary tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrolyte imbalances.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection/sepsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major organ failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paraneoplastic syndromes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer treatments – Many studies have focused upon chemotherapy’s effect on cognition, which is commonly referred to as “chemobrain.” As an example, a meta-analysis of five cross-sectional studies examined cognition in patients with breast cancer who were receiving or had received adjuvant chemotherapy (n = 208), and in controls (eg, breast cancer patients who did not receive adjuvant chemotherapy; n = 122) [<a href="#rid12">12</a>]. Executive functioning, language, memory, and spatial ability were each worse in patients treated with chemotherapy than controls, and the clinical differences were small to moderate.</p><p></p><p class="bulletIndent1">However, it is often difficult to attribute adverse cognitive changes solely to chemotherapy because many patients in these studies received other cancer treatments that can affect cognition, such as hormonal therapy (eg, corticosteroids), or radiation therapy and surgery involving the use of general anesthesia.</p><p></p><p class="bulletIndent1">Specific agents implicated in chemotherapy-related cognitive dysfunction include [<a href="#rid2">2,11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asparaginase</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">Chlorambucil</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Cytokines </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">Fluorouracil</a> </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a></p><p class="bulletIndent2"><span class="glyph">•</span>Interferon-alpha</p><p class="bulletIndent2"><span class="glyph">•</span>Interleukin-2</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">Procarbazine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">Vincristine</a></p><p></p><p class="bulletIndent1">Some data indicate that cognitive deficits related to cancer chemotherapy can become a long-term side effect that persists beyond treatment. (See  <a class="medical medical_review" href="/d/html/16347.html" rel="external">"Cognitive function after cancer and cancer treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other medications such as anticholinergics, as well as medications used for anxiety, agitation, and pain (eg, benzodiazepines, and opioids).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid psychiatric disorder<strong> </strong>– Patients with cancer often have psychiatric comorbidities that can lead to changes in cognition, including memory loss, impaired concentration, and decreased executive functioning. As an example, cognitive impairment may be a symptom of a depressive syndrome, such as major depression  (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 1</a>) or minor depression  (<a class="graphic graphic_table graphicRef106958" href="/d/graphic/106958.html" rel="external">table 2</a>), if the impairment occurs in conjunction with other depressive symptoms like dysphoria, anhedonia, and suicidal ideation or behavior. In addition, cancer patients, especially those who are older (eg, age ≥65 years) can present with cognitive decline secondary to a neurodegenerative disorder. Substance intoxication or withdrawal can also contribute to impaired cognition.</p><p></p><p class="headingAnchor" id="H2892211732"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Clinicians who want to screen patients with cancer for cognitive impairment can use either the Montreal Cognitive Assessment (MoCA) or the Mini Mental State Examination (MMSE) [<a href="#rid13">13,14</a>]. These standardized tests should be interpreted using age- and education-based normative values.</p><p></p><p>The MoCA is prone to yielding false positives. A prospective study of patients with brain tumors (n = 58) found that sensitivity for cognitive impairment was superior with the MoCA than the MMSE (62 versus 19 percent), but that specificity was superior with the MMSE (94 versus 56 percent) [<a href="#rid15">15</a>]. The MoCA is accessible online and in multiple languages at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmocacognition.com%2F&amp;token=b1YIhadNeg05BKW8lyJLG6R8uyFrFmc0HH66MOxJEZUbNyex33RJEu89nNTONJ3l&amp;TOPIC_ID=109994" target="_blank">MoCA website</a>. By contrast, the MMSE is copyrighted and must be purchased [<a href="#rid16">16</a>].</p><p>Additional information about the MoCA and MMSE is discussed separately. (See  <a class="medical medical_review" href="/d/html/14058.html" rel="external">"Mental status scales to evaluate cognition", section on 'Scales with moderate assessment times (5 to 15 minutes)'</a>.)</p><p class="headingAnchor" id="H4261159667"><span class="h1">DELIRIUM</span></p><p class="headingAnchor" id="H2954420937"><span class="h2">Overview</span><span class="headingEndMark"> — </span>A subset of patients with cognitive impairment can experience delirium, which is a neuropsychiatric syndrome that involves a disturbance in attention resulting from another medical illness, a medication or drug of abuse, or exposure to a toxin [<a href="#rid4">4</a>]. Delirium is common in patients with cancer and can cause distress in patients, caregivers, and families, due to frightening symptoms that may prevent family members from communicating with their loved one. In addition, delirium is associated with poor outcomes that include prolonged hospitalizations, and increased morbidity and mortality [<a href="#rid3">3,4</a>]. As an example, a study of hospitalized cancer patients who developed delirium (n = 140) found that 30-day mortality was 25 percent [<a href="#rid17">17</a>]. Early recognition of delirium may enable clinicians to treat the cause and avert any adverse outcomes [<a href="#rid11">11</a>].</p><p>The subsections below discuss delirium in patients with cancer. The clinical features, causes, assessment, diagnosis, and differential diagnosis of delirium in general clinical settings are discussed in detail separately, and delirium in patients approaching the end of life is also discussed separately. (See  <a class="medical medical_review" href="/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a> and  <a class="medical medical_review" href="/d/html/2199.html" rel="external">"Overview of managing common non-pain symptoms in palliative care", section on 'Delirium'</a>.)</p><p class="headingAnchor" id="H3255294771"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The incidence of delirium in patients with cancer varies among different subgroups and hospital settings, such as general medical or oncology units and palliative care units [<a href="#rid18">18</a>]. In addition, some reported rates may be inaccurate because they were based upon screening tools that were not validated for case ascertainment.</p><p>Delirium is a common complication of cancer and its treatment, especially in patients who are hospitalized and patients with advanced disease [<a href="#rid19">19,20</a>]. Reviews suggest that at a minimum, the prevalence of delirium in hospitalized patients is approximately 10 to 30 percent [<a href="#rid3">3,18</a>]. However, higher rates have been reported; as an example, a prospective study of 90 patients undergoing hematopoietic stem cell transplantation found that during five weeks of hospitalization, delirium occurred in 50 percent [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1176003624"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Delirium is a neuropsychiatric disorder that is caused by physiologic disturbances and often involves multiple etiologies [<a href="#rid3">3,4,11</a>]. Among patients with cancer, the potential causes of delirium overlap with those that can cause cognitive impairment in general. (See <a class="local">'Pathogenesis'</a> above.)</p><p>Additional information about the pathogenesis of delirium is discussed separately. (See  <a class="medical medical_review" href="/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2665505630"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>The clinical features of delirium in patients with cancer can include the following [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sudden onset of symptoms that typically fluctuate in severity during the day</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased level of consciousness (alertness or arousal)</p><p class="bulletIndent1"><span class="glyph">●</span>Attentional disturbances</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment as manifested by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Apraxia</p><p class="bulletIndent2"><span class="glyph">•</span>Agnosia</p><p class="bulletIndent2"><span class="glyph">•</span>Executive function (eg, planning) disturbances</p><p class="bulletIndent2"><span class="glyph">•</span>Language disturbances</p><p class="bulletIndent2"><span class="glyph">•</span>Memory impairment</p><p class="bulletIndent2"><span class="glyph">•</span>Visuospatial dysfunction</p><p class="bulletIndent2"><span class="glyph">•</span>Disorientation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delusions</p><p class="bulletIndent1"><span class="glyph">●</span>Mood symptoms (eg, dysphoria and lability)</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic findings (eg, asterixis, myoclonus, and tremor)</p><p class="bulletIndent1"><span class="glyph">●</span>Perceptual disturbances (illusions or hallucinations)</p><p class="bulletIndent1"><span class="glyph">●</span>Psychomotor activity is increased or decreased</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep-wake cycle disturbances</p><p class="bulletIndent1"><span class="glyph">●</span>Speech is incoherent</p><p class="bulletIndent1"><span class="glyph">●</span>Thought process is disorganized</p><p></p><p class="headingAnchor" id="H2007166687"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Screening tools can help clinicians diagnose delirium in medically ill patients. Among the instruments that have been validated in patients with cancer, we suggest the Confusion Assessment Method (CAM)  (<a class="graphic graphic_table graphicRef69489" href="/d/graphic/69489.html" rel="external">table 3</a>), which has been used in hospitalized patients [<a href="#rid3">3,18</a>]. Reasonable alternatives to the CAM include the Memorial Delirium Assessment Scale  (<a class="graphic graphic_form graphicRef56787 graphicRef69509" href="/d/graphic/56787.html" rel="external">form 1A-B</a>) and the Delirium Rating Scale-Revised 98. Delirium in cancer patients is frequently missed and is often misdiagnosed as akathisia, anxiety, dementia, depression, or psychosis [<a href="#rid11">11,22</a>].</p><p class="headingAnchor" id="H2005318120"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>According to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), the diagnosis of delirium requires each of the following criteria [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Disturbance in attention and awareness that develops quickly (usually hours to days) and tends to fluctuate each day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disturbance in cognition (eg, memory, orientation, language, visual spatial ability, and/or perception).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The disturbances in attention, awareness, and cognition are not better explained by another neurocognitive disorder and do not occur in the context of coma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence from the history, physical examination, or laboratory findings indicate that the disturbances are caused by a general medical condition, substance intoxication or withdrawal, and/or medication side effect.</p><p></p><p>Subtypes of delirium have been delineated, based upon the patient’s psychomotor behavior and level of arousal [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoactive subtype – Psychomotor retardation, lethargy, and decreased level of arousal. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperactive subtype – Restlessness, agitation, and hypervigilance. Mood lability, failure to cooperate with care, and psychotic features may also be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed level of activity – Level of activity fluctuates.</p><p></p><p>In addition, delirium is classified as acute (lasting a few hour or days) or persistent (lasting weeks to months) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H82958438"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16994.html" rel="external">"Patient education: Delirium (confusion) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/732.html" rel="external">"Patient education: Delirium (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3234646446"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive impairment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overview</strong> – Patients with cancer, including cancer located outside of the central nervous system, often report cognitive decline. However, the magnitude of the changes is typically modest, and functional impairment is usually minimal. Cognitive dysfunction can occur in several domains, including attention, concentration, executive function, information processing speed, and memory. The duration of cognitive impairment in patients with cancer varies and may extend beyond the acute illness and treatment. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevalence</strong> – Among patients with cancer, the prevalence of cognitive impairment after diagnosis of cancer but prior to treatment is approximately 20 to 30 percent. Cancer treatments are associated with neuropsychological deficits in up to 75 percent of patients. Increased age (eg, age ≥65 years) and decreased baseline cognitive reserve (intellectual capacity) appear to increase the risk of cognitive impairment in cancer patients. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathogenesis</strong> – It is likely that different mechanisms contribute to cognitive impairment in patients with cancer and that cognitive dysfunction in some patients reflects an interaction between multiple factors. Potential causes include brain metastases, dehydration, electrolyte imbalance, infection, major organ failure, and paraneoplastic syndromes, as well as chemotherapy. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening</strong> – Clinicians can screen patients with cancer for cognitive impairment with either the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmocacognition.com%2F&amp;token=b1YIhadNeg05BKW8lyJLG6R8uyFrFmc0HH66MOxJEZUbNyex33RJEu89nNTONJ3l&amp;TOPIC_ID=109994" target="_blank">Montreal Cognitive Assessment website</a> or the Mini Mental State Examination. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delirium</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overview</strong> – A subset of patients with cognitive impairment can experience delirium, which is a neuropsychiatric syndrome that involves a disturbance in attention resulting from another medical illness, a medication or drug of abuse, or exposure to a toxin. Delirium can cause distress in patients, caregivers, and families and is associated with increased morbidity and mortality. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevalence</strong> – At a minimum, the prevalence of delirium in patients hospitalized with cancer is approximately 10 to 30 percent. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathogenesis </strong>– Delirium is due to a physiologic disturbance and often involves multiple etiologies. Among patients with cancer, the potential causes overlap with those that can cause cognitive impairment in general. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical features</strong> – The clinical features of delirium in patients with cancer include sudden onset of symptoms that typically fluctuate in severity during the day, decreased level of consciousness, attentional disturbances, cognitive impairment as manifested by disturbances in executive functions and memory, neurologic findings, perceptual disturbances, sleep-wake cycle disturbances, incoherent speech, and disorganized thought process. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening</strong> – Screening tools can help clinicians diagnose delirium. Among the instruments that have been validated in patients with cancer, we suggest the Confusion Assessment Method  (<a class="graphic graphic_table graphicRef69489" href="/d/graphic/69489.html" rel="external">table 3</a>). (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – The diagnosis of delirium requires each of the following criteria:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Disturbance in attention and awareness that develops quickly (usually hours to days) and tends to fluctuate each day.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Disturbance in cognition (eg, memory and/or orientation).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The disturbances in attention, awareness, and cognition are not better explained by another neurocognitive disorder and do not occur in the context of coma.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Evidence from the history, physical examination, or laboratory findings indicate that the disturbances are caused by a general medical condition, substance intoxication or withdrawal, and/or medication side effect.</p><p></p><p>(See <a class="local">'Diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Magnuson A, Ahles T, Chen BT, et al. Cognitive Function in Older Adults With Cancer: Assessment, Management, and Research Opportunities. J Clin Oncol 2021; 39:2138.</a></li><li class="breakAll">Fernandez-Robles CG, Glass SP. Cancer: Psychiatric care of the oncology patient. In: Textbook of Medical Psychiatry, Summergrad P, Silbersweig DA, Muskin PR, Querques J (Eds), American Psychiatric Association Publishing, Washington, DC 2020. p.397.</li><li><a class="nounderline abstract_t">Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 2012; 30:1206.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li><a class="nounderline abstract_t">Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 2012; 30:3675.</a></li><li><a class="nounderline abstract_t">Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014; 26:102.</a></li><li><a class="nounderline abstract_t">Rodin G, Ahles TA. Accumulating evidence for the effect of chemotherapy on cognition. J Clin Oncol 2012; 30:3568.</a></li><li><a class="nounderline abstract_t">Ganz PA. "Doctor, will the treatment you are recommending cause chemobrain?". J Clin Oncol 2012; 30:229.</a></li><li><a class="nounderline abstract_t">Jean-Pierre P, Winters PC, Ahles TA, et al. Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Oncol Pract 2012; 8:30.</a></li><li><a class="nounderline abstract_t">Kobayashi LC, Cohen HJ, Zhai W, et al. Cognitive function prior to systemic therapy and subsequent well-being in older breast cancer survivors: Longitudinal findings from the Thinking and Living with Cancer Study. Psychooncology 2020; 29:1051.</a></li><li class="breakAll">Miller K, Massie MJ. Oncology. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liason Psychiatry, Third Edition, Levenson JL (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.625.</li><li><a class="nounderline abstract_t">Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59:60.</a></li><li><a class="nounderline abstract_t">Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.</a></li><li><a class="nounderline abstract_t">Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695.</a></li><li><a class="nounderline abstract_t">Olson RA, Iverson GL, Carolan H, et al. Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. J Neurooncol 2011; 105:337.</a></li><li class="breakAll">Folstein MF, Folstein SE, McHugh PR. Mini-Mental State Exam. In: Handbook of Psychiatric Measures, Second Edition, Rush Jr AJ, First MB, Blacker D (Eds), American Psychiatric Publishing, Inc, Arlington, VA 2008. p.403.</li><li><a class="nounderline abstract_t">Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol 2000; 57:1727.</a></li><li><a class="nounderline abstract_t">Sands MB, Wee I, Agar M, Vardy JL. The detection of delirium in admitted oncology patients: a scoping review. Eur Geriatr Med 2022; 13:33.</a></li><li><a class="nounderline abstract_t">Lawlor PG. Cancer patients with delirium in the emergency department: A frequent and distressing problem that calls for better assessment. Cancer 2016; 122:2783.</a></li><li><a class="nounderline abstract_t">Carlson B. Delirium in patients with advanced cancer. Lancet Oncol 2016; 17:e379.</a></li><li><a class="nounderline abstract_t">Fann JR, Hubbard RA, Alfano CM, et al. Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2011; 29:895.</a></li><li><a class="nounderline abstract_t">Wada T, Wada M, Wada M, Onishi H. Characteristics, interventions, and outcomes of misdiagnosed delirium in cancer patients. Palliat Support Care 2010; 8:125.</a></li></ol></div><div id="topicVersionRevision">Topic 109994 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043437" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cognitive Function in Older Adults With Cancer: Assessment, Management, and Research Opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043437" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cognitive Function in Older Adults With Cancer: Assessment, Management, and Research Opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412123" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence-based treatment of delirium in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412123" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence-based treatment of delirium in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008308" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716504" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence, mechanisms, and management of cancer-related cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Accumulating evidence for the effect of chemotherapy on cognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184392" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : "Doctor, will the treatment you are recommending cause chemobrain?".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22548008" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32154959" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cognitive function prior to systemic therapy and subsequent well-being in older breast cancer survivors: Longitudinal findings from the Thinking and Living with Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32154959" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cognitive function prior to systemic therapy and subsequent well-being in older breast cancer survivors: Longitudinal findings from the Thinking and Living with Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975700" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1202204" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817019" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21520004" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21520004" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115238" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Altered mental status in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35032322" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The detection of delirium in admitted oncology patients: a scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27454857" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cancer patients with delirium in the emergency department: A frequent and distressing problem that calls for better assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27498911" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Delirium in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21263081" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20307362" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characteristics, interventions, and outcomes of misdiagnosed delirium in cancer patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
